Biliary excretion of aztreonam in patients with biliary tract disease

O. Martinez, J. U. Levi, R. G. Devlin

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


The biliary excretion of aztreonam was studied in 10 post-cholecystectomy patients with T-tube biliary drainage (group A) and four other subjects with obstructive biliary tract disease wo had recent placement of external biliary drainage (group B). Maximum biliary levels ranged from 9.7 to 88.2 μg/ml (mean, 42.9 ± 7.9 μg/ml) and occurred 2.4 h after injection of a single 1-g dose intravenously. Peak biliary levels observed in group B patients were approximately one-third those in group A. Cumulative 12-h biliary excretion (group B) accounted for 0.18 ± 0.06% of the total dose. In the same period, urinary excretion accounted for 65 to 72% of the total dose. The lower biliary levels of aztreonam observed in group B patients relative to those in group A suggest that in patients with total biliary tract obstruction the liver may not recover full secretory capacity, at least within 3 to 7 days after biliary decompression.

Original languageEnglish (US)
Pages (from-to)358-361
Number of pages4
JournalAntimicrobial agents and chemotherapy
Issue number3
StatePublished - 1984

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Biliary excretion of aztreonam in patients with biliary tract disease'. Together they form a unique fingerprint.

Cite this